N-[4-(4-FLUORO-PHENYL)-THIAZOL-2-YL]-GUANIDINE
![]() |
- $168 - $623
- Product name: N-[4-(4-FLUORO-PHENYL)-THIAZOL-2-YL]-GUANIDINE
- CAS: 2438-34-8
- MF: C10H9FN4S
- MW: 236.27
- EINECS:
- MDL Number:MFCD06739729
- Synonyms:N-[4-(4-FLUORO-PHENYL)-THIAZOL-2-YL]-GUANIDINE;N-[4-(4-Fluorophenyl)-1,3-thiazol-2-yl]guanidine;Guanidine, [4-(4-fluorophenyl)-2-thiazolyl]- (9CI)
4 prices
Selected condition:
Brand
- Crysdot
- Matrix Scientific
Package
- 500mg
- 1g
- 5g
- ManufacturerCrysdot
- Product numberCD11159971
- Product description1-(4-(4-Fluorophenyl)thiazol-2-yl)guanidine 97%
- Packaging5g
- Price$617
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number080842
- Product descriptionN-[4-(4-Fluorophenyl)-1,3-thiazol-2-yl]guanidine
- Packaging500mg
- Price$168
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number080842
- Product descriptionN-[4-(4-Fluorophenyl)-1,3-thiazol-2-yl]guanidine
- Packaging1g
- Price$210
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number080842
- Product descriptionN-[4-(4-Fluorophenyl)-1,3-thiazol-2-yl]guanidine
- Packaging5g
- Price$623
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Crysdot | CD11159971 | 1-(4-(4-Fluorophenyl)thiazol-2-yl)guanidine 97% | 5g | $617 | 2021-12-16 | Buy |
Matrix Scientific | 080842 | N-[4-(4-Fluorophenyl)-1,3-thiazol-2-yl]guanidine | 500mg | $168 | 2021-12-16 | Buy |
Matrix Scientific | 080842 | N-[4-(4-Fluorophenyl)-1,3-thiazol-2-yl]guanidine | 1g | $210 | 2021-12-16 | Buy |
Matrix Scientific | 080842 | N-[4-(4-Fluorophenyl)-1,3-thiazol-2-yl]guanidine | 5g | $623 | 2021-12-16 | Buy |
Properties
Boiling point :398.3±34.0 °C(Predicted)
Density :1.50±0.1 g/cm3(Predicted)
pka :8.46±0.70(Predicted)
Density :1.50±0.1 g/cm3(Predicted)
pka :8.46±0.70(Predicted)
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|